The company said the site will be a “one-stop service for clinical supplies,” offering GMP storage, local labelling, secondary packaging, comparator sourcing, handling and distribution including cold chain, and returns management. The facility is aimed at regional and global pharma customers.
The company opened its first clinical services facility in Singapore in 2001 and will move the country’s operations to the new site on Toh Guan Road, Jurong East, part of a Singapore biotech hub. The 70,000 sq ft facility (6,500sqm) adds 60% more floor space and doubles previous cold chain capacity.
The facility has expanded Thermo Fisher’s storage system for its clinical supplies with a climate control energy use system that reduces the facility's carbon footprint, and a general building monitoring system that updates employees on the facility's conditions.
"Asia Pacific continues to be our fastest-growing market and a central contributor to our growth," said Leon Wyszkowski, a Thermo Fisher VP.
"For nearly 15 years, Singapore has been the central hub for our Asia-Pacific operations due to its strategic location. With the opening of our larger and well-equipped facility, we aim to continue to build on our Singapore facility further and on the expertise of our local team, to strengthen our regional and global presence in the clinical supplies industry."
Thermo Fisher Scientific last month reported Q3 earnings of $4.12bn, and earnings per share of $1.80. Earlier this year the division launched Ion S5 and Ion S5 XL next-generation sequencing platforms, new immunodiagnostic tests and instruments, and a high-throughput HPLC. It attributed revenue growth to demand from Chinese biopharma, among other factors.